Business
Cosmos Health Successfully Submits Tender for C-Scrub Wash Chlorhexidine 4% to Supply NHS Scotland
CHICAGO, IL / ACCESSWIRE / July 25, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global
About this update from Cosmos Health Inc.
[{"type":"text","content":"CHICAGO, IL / ACCESSWIRE / July 25, 2024 / Cosmos Health Inc. (\"Cosmos Health\" or the \"Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that its wholly-owned subsidiary, Decahedron Ltd (\"Decahedron\"), has successfully submitted its tender to supply the National Health Service (NHS) in Scotland with its antimicrobial wash, C-Scrub Wash Chlorhexidine 4% (\"C-Scrub\").Decahedron has been invited to participate in the NHS Scotland tender for \"Antiseptic Solutions and Hand Hygiene Products.\" Participation in this tender process is conducted on an invitation-only basis. The Company has successfully submitted its tender to supply the NHS in Scotland with its C-Scrub antimicrobial wash in 250ml and 500ml pack sizes.C-Scrub, with 4% chlorhexidine gluconate, offers immediate and prolonged antimicrobial action for up to 6 hours, even in the presence of biological fluids. Ideal for routine hand disinfection, it targets bacteria, viruses, and fungi without promoting resistance. Suitable for iodine-sensitive users, it includes emollients for skin health and is cosmetically friendly. C-Scrub is perfect for healthcare environments, including hospitals, clinics, surgery rooms, emergency departments, wards, ICUs, and other medical facilities. Cosmos Health expects to participate in additional tenders across the United Kingdom, including those with NHS England.According to Grand View Research, the antibacterial products market in the UK is expected to grow from $656.5 million in 2020 to $733.0 million by 2028, reflecting a compound annual growth rate (CAGR) of 1.4%.Suhel Bhutawala, Director of Decahedron, stated: \"We are delighted to have been invited to participate in the tender for antiseptic solutions and hand hygiene products. Our team has successfully submitted our proposal, and we eagerly look forward to supplying NHS Scotland with our C-Scrub antimicrobial wash.\"Greg Siokas, CEO of Cosmos Health, stated: \"We are pleased to announce that we have successfully submitted our tender for C-Scrub and look forward to becoming a trusted supplier to NHS Scotland. The UK market is of great significance to Cosmo...